Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

AnaptysBio discontinues ANB032 for atopic dermatitis after a trial failure, refocusing on autoimmune assets with upcoming ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

Dupilumab significantly reduces severe exacerbations and improves lung function in children with moderate-to-severe type 2 ...

Earlier this year, researchers of Brigham and Women’s Hospital Harvard Medical School looked at clinical trials to show how six biologics, in particular, improve lung function; cut down on steroid use ...

Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether ...

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

Upadacitinib was superior to dupilumab for the treatment of atopic dermatitis in the head and neck, trunk, upper limbs, and lower limbs.

Dupixent is used for eczema, COPD, and certain types of asthma. The most common side effects may include injection site reactions, pink eye, eyelid inflammation, cold sores, and mouth or throat pain.